vaccinogeninc.com
Vaccinogen Treating Colon Cancer with OncoVAX Immunotherapy
Andrew L. Tussing. Michael G. Hanna, Jr., Ph.D. Peter Morsing, Ph.D. Jason D. Howard, Ph.D. Earl V. Miller, MBA. Drs Dinand van der Linde, MSc, MA. HC Hoover, Jr., M.D. Andrew L. Tussing. Michael G. Hanna, Jr., Ph.D. Human Monoclonal Antibodies (HuMabs) Program. OncoVax Fact Sheet (PDF). Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 1. Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 2. Manufacturing - Stage 1. Manufacturing - Stage 2. Manufacturing - Stage 3. Stage III Colon Cancer.
vaccinogeninc.investorroom.com
Investor Welcome - Vaccinogen
Human Monoclonal Antibodies (HuMabs) Program. OncoVAX For Colon Cancer. Stage III Colon Cancer. Additional Potential OncoVAX applications. Human Monoclonal Antibodies (HuMabs) Program. Vaccinogen is a biotechnology company with more than three decades of research into combating cancer by using the body’s own immune system. It is the producer of OncoVAX, an immunotherapy for Stage II colon cancer. May 5, 2015. Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board. Feb 24, 2015.